240 related articles for article (PubMed ID: 20660041)
1. Organic cation transporter 1 polymorphisms predict the metabolic response to metformin in women with the polycystic ovary syndrome.
Gambineri A; Tomassoni F; Gasparini DI; Di Rocco A; Mantovani V; Pagotto U; Altieri P; Sanna S; Fulghesu AM; Pasquali R
J Clin Endocrinol Metab; 2010 Oct; 95(10):E204-8. PubMed ID: 20660041
[TBL] [Abstract][Full Text] [Related]
2. Association between Polymorphisms of
Chang HH; Hsueh YS; Cheng YW; Ou HT; Wu MH
Int J Mol Sci; 2019 Apr; 20(7):. PubMed ID: 30959948
[TBL] [Abstract][Full Text] [Related]
3. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics.
Shu Y; Brown C; Castro RA; Shi RJ; Lin ET; Owen RP; Sheardown SA; Yue L; Burchard EG; Brett CM; Giacomini KM
Clin Pharmacol Ther; 2008 Feb; 83(2):273-80. PubMed ID: 17609683
[TBL] [Abstract][Full Text] [Related]
4. Metformin resistance alleles in polycystic ovary syndrome: pattern and association with glucose metabolism.
Schweighofer N; Lerchbaum E; Trummer O; Schwetz V; Pieber T; Obermayer-Pietsch B
Pharmacogenomics; 2014 Feb; 15(3):305-17. PubMed ID: 24533710
[TBL] [Abstract][Full Text] [Related]
5. Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.
Fulghesu AM; Romualdi D; Di Florio C; Sanna S; Tagliaferri V; Gambineri A; Tomassoni F; Minerba L; Pasquali R; Lanzone A
Hum Reprod; 2012 Oct; 27(10):3057-66. PubMed ID: 22786777
[TBL] [Abstract][Full Text] [Related]
6. The Pharmacogenetics of Metformin in Women with Polycystic Ovary Syndrome: A Randomized Trial.
Pedersen AJT; Stage TB; Glintborg D; Andersen M; Christensen MMH
Basic Clin Pharmacol Toxicol; 2018 Feb; 122(2):239-244. PubMed ID: 28834135
[TBL] [Abstract][Full Text] [Related]
7. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
8. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
9. Genotype-dependent effects of inhibitors of the organic cation transporter, OCT1: predictions of metformin interactions.
Ahlin G; Chen L; Lazorova L; Chen Y; Ianculescu AG; Davis RL; Giacomini KM; Artursson P
Pharmacogenomics J; 2011 Dec; 11(6):400-11. PubMed ID: 20567254
[TBL] [Abstract][Full Text] [Related]
10. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
11. Peripheral blood-derived cytokine gene polymorphisms and metabolic profile in women with polycystic ovary syndrome.
Sóter MO; Ferreira CN; Sales MF; Candido AL; Reis FM; Milagres KS; Ronda C; Silva IO; Sousa MO; Gomes KB
Cytokine; 2015 Dec; 76(2):227-235. PubMed ID: 26141422
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.
Shu Y; Sheardown SA; Brown C; Owen RP; Zhang S; Castro RA; Ianculescu AG; Yue L; Lo JC; Burchard EG; Brett CM; Giacomini KM
J Clin Invest; 2007 May; 117(5):1422-31. PubMed ID: 17476361
[TBL] [Abstract][Full Text] [Related]
13. The effects of metformin on metabolic and cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Sahin Y; Unluhizarci K; Yilmazsoy A; Yikilmaz A; Aygen E; Kelestimur F
Clin Endocrinol (Oxf); 2007 Dec; 67(6):904-8. PubMed ID: 17666089
[TBL] [Abstract][Full Text] [Related]
14. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study.
Orio F; Palomba S; Cascella T; De Simone B; Manguso F; Savastano S; Russo T; Tolino A; Zullo F; Lombardi G; Azziz R; Colao A
J Clin Endocrinol Metab; 2005 Nov; 90(11):6072-6. PubMed ID: 16118336
[TBL] [Abstract][Full Text] [Related]
15. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
Romualdi D; De Cicco S; Tagliaferri V; Proto C; Lanzone A; Guido M
J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
17. Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response.
Palomba S; Falbo A; Russo T; Orio F; Tolino A; Zullo F
Hum Reprod; 2010 Apr; 25(4):1005-13. PubMed ID: 20106839
[TBL] [Abstract][Full Text] [Related]
18. Use of metformin in polycystic ovary syndrome.
Mathur R; Alexander CJ; Yano J; Trivax B; Azziz R
Am J Obstet Gynecol; 2008 Dec; 199(6):596-609. PubMed ID: 19084097
[TBL] [Abstract][Full Text] [Related]
19. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
20. The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Hahn S; Frey UH; Siffert W; Tan S; Mann K; Janssen OE
Eur J Endocrinol; 2006 Nov; 155(5):763-70. PubMed ID: 17062894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
